Policy and strategy Tirzepatide (Mounjaro®) for the management of obesity and overweight (WHC/2025/018) Letter to health boards, general practitioners and pharmacies about medication for weight management. Read details on this page Part of: Health circulars: 2024 to 2027 and Medicines and medical devices (Sub-topic) First published: 8 May 2025 Last updated: 7 July 2026 Documents Tirzepatide (Mounjaro®) for the management of obesity and overweight (WHC/2025/018) Tirzepatide (Mounjaro®) for the management of obesity and overweight (WHC/2025/018) , HTML HTML Details This circular has been superseded by WHC/2025/043. Related Obesity (Sub-topic)New clinical pathway for treating and managing obesity (WHC/2025/043)
